DoctoriumGP
Clinical summary
Clinical summary for review

Georgina Whetton

DOB 21 April 1954 (72) · Female · 157 cm · 66.2 kg on 29 July 2026 · BMI 26.8
Prepared for Dr Gemma Lewis MRCS MRCGP, Clinical Director, DoctoriumGP
9 September 2026
Private and confidential. Breast histology awaited.
PurposeSix items are put forward for a note to the patient’s GP. Each carries its evidence, the inference drawn, and a draft line. Dr Lewis approves, amends or strikes each one.
1. Presenting situation

Breast imaging in September 2026 following a mammogram, ultrasound and core biopsy, with a further ultrasound. The patient reports the breast lesion was graded 5 and one axillary node graded 3. The clinician quoted a probability of malignancy of about 95%. Histology is awaited.

Not yet on record: the side, the written imaging report, the dates of clinic and biopsy, and whether the node was sampled. These will be added when the letter is available.

2. Items for the GP note, with working

Item 1. Antihypertensive therapy stopped 22 August 2026

Evidence
FindingValueDateSource
Bisoprolol 2.5 mg and candesartan 8 mg both stopped by the patientStopped22 Aug 2026Prescription annotated by patient; her message 9 Sep 2026
GP contact around the stopQRISK3 calculated 20 Aug 2026; repeat printed 13 Aug 2026Aug 2026NHS App
Home BP on treatment, February 2026113/65 and 123/5910 and 11 Feb 2026Apple Health export
Home BP on treatment, 7 to 21 Aug 2026Mean 129/55, 3 readingsAug 2026Health app
Home BP off treatment, 22 Aug to 5 Sep 2026Mean 149/64, 21 readings, six at or above 160 systolicAug to Sep 2026Health app
Most recent readings176/70 at 06:00 and 164/70 at 09:215 Sep 2026Health app
Pre-treatment baselineMean 157/67, peak 185/64, 18 readings6 to 13 Feb 2018Apple Health export
Sodium while on candesartan132, then 131 with a lab request to repeat11 Apr 2025, 15 May 2026NHS App
Sodium on repeat, still on candesartan≈137Mid-2026NHS App
Inference

Systolic has risen by about 20 mmHg within a fortnight of stopping both agents. The earlier low sodium normalised on the repeat while she was still taking candesartan, so it does not on its own argue against restarting it.

Draft line for GP
“Home blood pressure off treatment since 22 August averages 149/64 over 21 readings with a peak of 176/70 on 5 September. On bisoprolol 2.5 mg and candesartan 8 mg it averaged 118/62 in February and 129/55 in early August. Breast surgery is likely within weeks. Please review antihypertensive therapy ahead of pre-operative assessment. [Dr Lewis: restart previous regimen / candesartan alone / other].”

Item 2. Simvastatin stopped 22 August 2026

Evidence
FindingValueDateSource
Simvastatin 40 mg at night stopped by the patientStopped22 Aug 2026Prescription annotated by patient
QRISK310.5%20 Aug 2026NHS App
Total cholesterol on treatment3.315 May 2026NHS App
LDL on treatment1.215 May 2026NHS App
HDL on treatment1.6215 May 2026NHS App
Triglycerides on treatment1.1 (2.1 the year before)15 May 2026NHS App
Type 2 diabetes on record; HbA1c now ≈36See item 42026NHS App
Inference

The stop coincides with a QRISK3 above 10% and a diabetes diagnosis on the record. No off-treatment lipid profile exists yet.

Draft line for GP
“Simvastatin 40 mg was stopped on 22 August with QRISK3 recorded at 10.5% on 20 August and a diabetes diagnosis on record. [Dr Lewis: please restart / repeat lipids off treatment in 8 weeks and review / no action].”

Item 3. Vaginal estradiol

Evidence
FindingValueDateSource
Estradiol 10 microgram pessaries issuedTwo issuesDec 2025, Jan 2026NHS App medication record
Breast team’s advice as reported by the patientMay continue if she feels she needs itSep 2026Patient’s message 9 Sep 2026
Patient’s question, verbatim“they said I can still take the estrogen if I still think I need it, what do you think, should I”9 Sep 2026Patient’s message
Receptor statusNot yet known Histology awaited
Inference

The patient wants a second opinion from Dr Lewis on continuing local oestrogen with breast histology pending.

Draft line for GP
None required unless Dr Lewis wants the GP to action a change. Dr Lewis’s answer goes to the patient directly. [Dr Lewis: continue / pause until receptor status known / stop].

Item 4. Metformin stopped 22 August 2026 (for information, no action proposed)

Evidence
FindingValueDateSource
Metformin MR 500 mg twice daily stopped by the patientStopped22 Aug 2026Prescription annotated by patient
HbA1c series55, 48, 50 then ≈37, ≈36, ≈362023 to Aug 2026NHS App chart; 50 dated 11 Apr 2025
Fasting capillary glucose, 24 readingsMean 5.5, range 4.5 to 6.05 Jul to 1 Sep 2026Health app
Fasting glucose after the stop, 8 readingsMean 5.35, range 4.5 to 5.822 Aug to 1 Sep 2026Health app
Weight loss context81.0 kg to 62.0 kg, GLP-1 agonist privately sourced, now stoppedJul 2025 to Feb 2026Tanita; patient
Inference

Glycaemic control has held off metformin over the ten days of readings available.

Draft line for GP
“Metformin was stopped on 22 August. Home fasting glucose since averages 5.35 mmol/L. HbA1c ≈36. Please confirm the diabetes register status and the HbA1c recall interval.” [Dr Lewis: include / omit].

Item 5. Haemoglobin trend

Evidence
FindingValueDateSource
Haemoglobin13911 Apr 2025NHS App
Haemoglobin14315 May 2026NHS App
Haemoglobin≈132Aug 2026NHS App chart
Red cell count4.53 then ≈4.215 May 2026, Aug 2026NHS App
Haematocrit0.417 then ≈0.3915 May 2026, Aug 2026NHS App
Platelets289 then ≈25015 May 2026, Aug 2026NHS App
Ferritin142 µg/L12 Aug 2026NHS App
White cells and differentialAll within rangeAug 2026NHS App
Inference

A fall of about 11 g/L over three months with red cell count, haematocrit and platelets moving the same way; every value remains within range and iron stores are replete.

Draft line for GP
“Haemoglobin has fallen from 143 (May) to about 132 (August) with a parallel fall in red cell count, haematocrit and platelets, all still within range; ferritin 142. [Dr Lewis: please repeat FBC before pre-operative assessment / no action].”

Item 6. Sleep-disordered breathing, not formally assessed

Evidence
FindingValueDateSource
Breathing disturbances per hour, overnight10 to 15Sep 2025 to Feb 2026Apple Watch
Overnight SpO2 nadir71 to 77%Sep 2025 to Feb 2026Apple Watch
Daytime SpO296 to 100%Sep 2025 to Feb 2026Apple Watch
Average sleep, deep sleep5.6 to 6.0 h, 0.4 to 0.6 hSep 2025 to Feb 2026Apple Watch
Snoring and suspected apnoeaSelf-reportedJun 2025Patient symptom list
Formal sleep studyNone on record  
BMI26.829 Jul 2026Tanita
Inference

Consumer-device data only, but consistent with moderate nocturnal desaturation.

Draft line for GP
“Consumer wearable data over five months show 10 to 15 breathing disturbances an hour and overnight oxygen saturation dips to the low 70s; she reports snoring. No sleep study on record. [Dr Lewis: please refer for sleep assessment / flag to the pre-operative team only].”
Your decisions 0 of 6 decided
3. Medication record

Source: NHS repeat prescription printed 13 August 2026 (review date on the print: 23 March 2026), annotated by the patient. Her message of 9 September 2026: “I stopped taking the above tablets on the marked x 22/08/26. Only taking omeprazole, betahistine and vitamins on a daily basis, the others as and when required.”

Stopped 22 August 2026

DrugDoseIndication on record
Bisoprolol2.5 mg each morningCardiovascular
Candesartan8 mg once dailyHypertension
Metformin MR500 mg twice daily with mealsType 2 diabetes
Simvastatin40 mg at nightCholesterol
Solifenacin5 mg once dailyOveractive bladder

Continuing daily

DrugDose
Omeprazole20 mg once daily
Betahistine8 mg, taken daily by the patient (prescribed as required)
VitaminsUnspecified, over the counter

As required

DrugNote
Buscopan 10 mgUp to three times daily, new in 2026 (fifth issue in twelve months)
Flixonase 50 microgram nasal sprayOne spray each nostril daily
Xailin Plus HA 0.2% eye dropsPreservative free, four times daily

Episodic in the last twelve months: estradiol 10 microgram pessaries (December 2025, January 2026); naproxen 250 mg (September 2025); dexamethasone, neomycin and acetic acid ear spray (January 2026).

Not on the NHS record: a privately sourced GLP-1 receptor agonist, agent and dose not recorded, used from around July 2025 to mid-June 2026. One injection in the three months to September 2026. Now stopped. It accounts for the 19 kg weight loss between July 2025 and February 2026 and the 4.2 kg regain to July 2026.

4. Blood pressure

Source: Health app entries on the patient’s phone, supplied 9 September 2026 (August to September 2026), and her Apple Health export of 12 February 2026 (earlier clusters). All are manual entries from a home cuff.

Summary by period

PeriodReadingsSystolic mean (range)Diastolic mean (range)Treatment
6 to 13 Feb 201818157 (126 to 185)67 (56 to 83)Pre-treatment baseline
11 Jul to 26 Aug 202522127 (108 to 140)58 (46 to 68)Bisoprolol and candesartan, during weight loss
10 to 11 Feb 20262118 (113 to 123)62 (59 to 65)Bisoprolol and candesartan
7 to 21 Aug 20263129 (113 to 137)55 (52 to 60)Bisoprolol and candesartan
22 Aug to 5 Sep 202621149 (126 to 176)64 (52 to 75)Off both from 22 Aug

24 readings, 7 August to 5 September 2026

60 80 100 120 140 160 180 22 Aug: antihypertensives stopped 7 Aug 14 Aug 22 Aug 29 Aug 5 Sep
Systolic Diastolic Systolic ≥160 22 Aug: antihypertensives stopped

No readings are on record between 12 February and 7 August 2026.

DateTimeReading
7 Aug08:10113/60
21 Aug08:23136/52
21 Aug09:19137/52
22 Aug09:32147/53
22 Aug20:26140/59
23 Aug07:29166/72
23 Aug09:10136/60
23 Aug18:56136/56
24 Aug11:35166/73
24 Aug14:50128/65
25 Aug10:43147/60
26 Aug09:51126/52
26 Aug17:30134/59
27 Aug09:10164/70
27 Aug15:32144/59
28 Aug07:37166/67
29 Aug09:56150/59
29 Aug09:58139/60
30 Aug11:49140/75
31 Aug07:05150/64
1 Sep14:57147/62
4 Sep08:49156/72
5 Sep06:00176/70
5 Sep09:21164/70
5. Glucose

Source: Health app fasting capillary glucose entries, supplied 9 September 2026. 24 readings, 5 July to 1 September 2026. Mean 5.5 mmol/L, range 4.5 to 6.0. The eight readings after metformin stopped on 22 August: mean 5.35, range 4.5 to 5.8.

5 Jul1 Sep
DateTimemmol/L
5 Jul07:055.4
7 Jul08:035.4
15 Jul08:186.0
17 Jul06:265.9
20 Jul07:594.7
24 Jul06:545.7
26 Jul06:215.5
30 Jul09:065.7
1 Aug07:005.2
4 Aug07:495.4
7 Aug08:056.0
17 Aug07:335.7
18 Aug06:425.8
19 Aug08:205.6
20 Aug07:245.2
21 Aug09:135.8
22 Aug07:245.6
23 Aug06:385.5
24 Aug09:014.5
25 Aug09:305.7
26 Aug06:595.8
30 Aug08:045.4
31 Aug07:035.2
1 Sep07:575.1

HbA1c (mmol/mol, range 20 to 41): ≈55H (2023), ≈48H (2024), 50H (11 April 2025), then ≈37, ≈36, ≈36 across three samples between late 2025 and August 2026.

6. Cumulative results

Reference ranges are the reporting laboratory’s own. Blank cells mean not tested or not supplied.

Key: ≈ read from the NHS App trend chart, accurate to about one unit. H and L against the laboratory’s own range.

6.1 Renal profile and electrolytes

TestAug 2024Late 202411 Apr 202515 May 2026Mid 2026UnitsRange
Sodium≈129L≈134 to ≈135132L131L (lab: repeat in one month)≈137mmol/L133 to 146
Potassium≈3.4L≈4.3 to ≈5.05.14.7≈4.6mmol/L3.5 to 5.3
Urea≈4.3≈3.4 to ≈5.74.13.8≈5.0mmol/L2.5 to 7.8
Creatinine≈42L≈41 to ≈45L39L41L≈45µmol/L45 to 84
eGFR (MDRD)  >90>90>90 (30 Jun 2026)mL/min/1.73m² 

6.2 Full blood count

TestApr 2024Aug 202411 Apr 202515 May 2026Aug 2026UnitsRange
Haemoglobin≈144≈139139143≈132g/L115 to 165
Red cell count≈4.55≈4.554.414.53≈4.210¹²/L3.80 to 5.80
Haematocrit≈0.41≈0.4070.4080.417≈0.39L/L0.36 to 0.47
MCH≈31.5≈30.6≈31.5≈31.5≈31.6pg27 to 32
White cell count≈8.3≈9.48.506.52≈6.310⁹/L4.0 to 11.0
Neutrophils  within range not supplied10⁹/L 
Lymphocytes≈2.3≈2.75≈2.6≈2.1≈2.410⁹/L1 to 4
Monocytes≈0.5≈0.55≈0.47≈0.46≈0.4510⁹/L0.2 to 1.2
Eosinophils≈0.17≈0.19≈0.18≈0.12≈0.110⁹/L0.04 to 0.4
Basophils≈0.10≈0.09≈0.05≈0.05≈0.0410⁹/L0 to 0.1
Large immature cells    0.0210⁹/L0 to 0.5
Platelets≈315≈310304289≈25010⁹/L150 to 450

Laboratory comment on the August 2026 count: “05.12.2025: Please note updated reference range for Monocytes. Please note this assay is not currently UKAS accredited, pending assessment.”

6.3 Iron

Test26 Sep 201331 Oct 201327 Apr 202212 Aug 2026Units
Ferritin320301493142ng/mL to 2022, µg/L in 2026

6.4 Liver function

Test25 Jan 202412 Apr 202427 Aug 202411 Apr 202515 May 2026UnitsRange
ALT48H61H66H67H33IU/L0 to 34
ALP879210012479IU/L30 to 130
GGT   165Hnot suppliedU/L0 to 38
Bilirubin≈8≈10≈779µmol/L0 to 21
Albumin≈41≈42≈403941g/L35 to 50

Earlier ALT on the chart: ≈58 in October 2023.

6.5 Lipids

TestSep 2023202411 Apr 202515 May 2026UnitsRange
Total cholesterol≈2.9≈3.23.23.3mmol/L0 to 5.0
HDL≈1.2≈1.41.451.62mmol/L1.20 to 2.10
LDL≈0.8≈0.70.81.2mmol/L0 to 3.0
Triglycerides≈1.9H≈2.5H2.1H1.1mmol/L0 to 1.7
Non-HDL cholesterol1.7 (12 Sep 2023; 2.0 on 27 Jun 2023) 1.81.7mmol/L0 to 3.8
Cholesterol to HDL ratio 2.3 (12 Apr 2024)2.22.0  

All May 2026 lipids were taken on simvastatin 40 mg.

6.6 Diabetes

Test2023202411 Apr 2025Late 2025 to Aug 2026 (three samples)UnitsRange
HbA1c (IFCC)≈55H≈48H50H≈37, ≈36, ≈36mmol/mol20 to 41
QRISK3   10.5% (20 Aug 2026)  

6.7 Thyroid

Test27 Apr 202216 Jan 202312 Apr 202411 Apr 202515 May 2026UnitsRange
TSH0.861.151.030.740.87mIU/L0.38 to 5.33

6.8 Urine

Test22 Feb 202127 Apr 2022May 202218 Apr 202312 Apr 202411 Apr 202518 May 2026UnitsRange
Albumin   3.0<3.0<7.07.5mg/L 
Creatinine8.26.03.14.61.82.93.7mmol/L 
ACR     <2.42.0mg/mmol0 to 2.9

6.9 Not seen in any 2026 result

GGT, a date-stamped HbA1c value, neutrophil count.

7. Body composition, fitness and other history

Tanita, 29 July 2026 against 23 February 2026: weight 66.2 kg (62.0), body fat 32.4% (28.9%), fat mass 21.4 kg (17.9), muscle mass 42.5 kg (41.8, the highest of seven scans), BMI 26.8 (25.1), visceral fat rating 7 (6), bone mass 2.3 kg, BMR 1,322 kcal. Peak weight 81.0 kg in July 2025.

Apple Watch data to 12 February 2026: eleven ECG recordings June to December 2025, all sinus rhythm; resting heart rate 67 (63 in mid-2025); HRV 23.6 ms; VO2 max estimate 24.6; six-minute walk 463 m (peak 500 m in October 2025); walking steadiness 65 to 73%; walking asymmetry up to 17.6% in January 2026; average sleep 5.6 to 6.0 hours.

Imaging on record: right shoulder x-ray 9 February 2026, mild to moderate acromioclavicular joint degeneration, glenohumeral joint preserved, no calcific tendinopathy, incidental calcified granulomas in the right lung.

Self-reported history (June 2025 symptom list): arthritis in multiple joints, progressive; significant hair loss over six years, attributed by her to medication; contact dermatitis; recurrent respiratory infections; slow wound healing with monthly finger splits; chronic fatigue; GORD; constipation; frequent headaches; vertigo; uterine prolapse; snoring and suspected sleep apnoea; haemorrhoids; allergic rhinitis.

8. Proposed interim measures, for Dr Lewis to confirm or amend
  1. GP review this week on blood pressure, with the home readings in section 4 and the surgical context stated. Home readings continue, morning and evening.
  2. Full blood count and renal profile repeated before pre-operative assessment rather than at it.
  3. At pre-operative assessment, declare: the breathing disturbance data, the estradiol pessaries, the medication stops of 22 August, and the GLP-1 history.
  4. Naproxen and any supplement with an antiplatelet effect stopped a week before surgery.
  5. Prehabilitation from now: protein at each meal, daily walking, balance work, and physiotherapy for right shoulder range of movement given the acromioclavicular findings.
  6. Influenza and COVID vaccination now, ahead of any theatre date or systemic treatment.
  7. At the results appointment: written histology with grade and receptor status, MDT date, breast care nurse contact, staging plan, and a baseline DEXA if endocrine therapy is planned.
9. Sources